Beam Therapeutics (BEAM)’ treatment of alpha-1 antitrypsin deficiency was granted FDA orphan designation status, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
- Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
- Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating
- Beam Therapeutics: Promising Advancements in Base Editing and Strong Financial Position Support Buy Rating
- Beam Therapeutics price target lowered to $55 from $78 at Guggenheim